Sacituzumab Govitecan and the New Standard of Care: What the NCCN Update Means for First-Line Metastatic TNBC

Antibody-drug conjugates are increasingly taking center stage in metastatic triple-negative breast cancer (TNBC)—and the latest NCCN guidelines reflect that shift. Sacituzumab govitecan (Trodelvy; Gilead) has earned a Category 1 preferred designation for first-line treatment, a milestone that carries real consequences for how clinicians approach biomarker testing, treatment sequencing, and patient conversations. Pharmacy Times spoke with Jordan Hill, PharmD, BCOP, to unpack what drove the guideline change, how it's playing out in clinical practice, and what the emerging ASCENT-03 and ASCENT-04 data could mean for the future of care in this setting.